NRX — Nurexone Biologic Share News
0.000.00%
Last trade - 00:00- CA$51.09m
- CA$49.75m
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
Biotechnology firm NurExone's Q3 net loss widens
Brief: NurExone Biologic Announces Preclinical Evidence of Structural Repair In Injured Spinal Cord Tissue Following ExoPTEN Treatment
Brief: NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation
Brief: Nurexone Biologic Announces U.S. Uplisting Intention And Closes C$2.3 Million Private Placement
Brief: ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
Brief: Nurexone Announces Promising Preclinical Results In Restoring Vision After Optic Nerve Damage
Brief: NurExone Biologic Announces Private Placement of up to $2 Mln and Closes First Tranche for $1.61 Mln
Brief: Nurexone Demonstrates Extended Therapeutic Window Of Exopten Post Spinal-Cord Injury
Brief: Nurexone Biologic Achieves Key Advances In Exosome Manufacturing Process
Brief: Nurexone Announces Further Expansion Of ExoPTEN Patent Coverage
Brief: In Preparation For Expected Human Clinical Trials, Nurexone Signs Agreement For Large Scale Preclinical Testing For Its Spinal Cord Injury Therapy, Exopten
Brief: Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
Brief: Nurexone Biologic Extends Spinal Cord Injury Therapy Portfolio With New Rna Sequences Promoting Healing And Regeneration
Brief: Nurexone Biologic Receives FDA Orphan-Drug Designation
Brief: Nurexone Secures Eureka Grant For Collaborative Partnership To Expand To Chronic Spinal Cord Injury Therapy